Skip to content

Inhaled ColiFin® in adult bronchiectasis patients with new asymptomatic Pseudomonas aeruginosa infection – an open-label, proof of concept - randomized controlled trial (DZL-Eradicate)

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-509277-22-00
Acronym
KKS-287
Enrollment
66
Registered
2024-09-17
Start date
2022-06-22
Completion date
Unknown
Last updated
2025-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchiectasis

Brief summary

Proportion of sputum/airway culture negativity (=3 consecutively negative sputum/airway cultures) for PA 28 weeks after randomisation

Detailed description

Change in PA (semi-quantitative) in sputum from baseline to Day 29 of treatment, Rate of pulmonary exacerbations in 28 weeks after randomisation, Rate of severe exacerbations (hospitalizations) in 28 weeks after randomisation, Time to first pulmonary exacerbation after start of treatment, Change from baseline in respiratory symptom domain of the SGRQ ountil 28 weeks after randomization, Change from baseline in quality of life measured by SGRQ until 28 weeks after randomization, Change from baseline in quality of life measured by QOL-B until 28 weeks after randomization, Change from baseline on change in ppFEV1, Change in antibiotic susceptibility in isolated sputum PA until 28 weeks after randomization

Interventions

DRUGColiFin® 2 Millionen I.E. Pulver zur Herstellung einer Lösung für einen Vernebler

Sponsors

Philipps-Universitaet Marburg
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Proportion of sputum/airway culture negativity (=3 consecutively negative sputum/airway cultures) for PA 28 weeks after randomisation

Secondary

MeasureTime frame
Change in PA (semi-quantitative) in sputum from baseline to Day 29 of treatment, Rate of pulmonary exacerbations in 28 weeks after randomisation, Rate of severe exacerbations (hospitalizations) in 28 weeks after randomisation, Time to first pulmonary exacerbation after start of treatment, Change from baseline in respiratory symptom domain of the SGRQ ountil 28 weeks after randomization, Change from baseline in quality of life measured by SGRQ until 28 weeks after randomization, Change from baseline in quality of life measured by QOL-B until 28 weeks after randomization, Change from baseline on change in ppFEV1, Change in antibiotic susceptibility in isolated sputum PA until 28 weeks after randomization

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026